Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4299686
Max Phase: Preclinical
Molecular Formula: C160H237N41O47
Molecular Weight: 3486.90
Molecule Type: Unknown
Associated Items:
ID: ALA4299686
Max Phase: Preclinical
Molecular Formula: C160H237N41O47
Molecular Weight: 3486.90
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCC(NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(=O)O)C(=O)NC(Cc1cccc2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H](C(=O)N[C@@H](CCCCN)C(N)=O)[C@H](C)O)[C@@H](C)CC)[C@H](C)CC)[C@@H](C)CC)[C@H](C)O
Standard InChI: InChI=1S/C160H237N41O47/c1-18-22-46-98(181-139(228)101(51-53-122(211)212)182-147(236)112(67-124(215)216)193-154(243)116(75-203)196-143(232)105(59-87-37-25-23-26-38-87)187-153(242)115(74-202)178-121(210)73-173-136(225)111(66-123(213)214)177-120(209)72-172-135(224)95(162)63-92-71-169-76-174-92)137(226)190-110(65-119(165)208)152(241)201-131(86(17)205)159(248)199-129(82(13)21-4)157(246)194-103(57-78(7)8)142(231)192-114(69-126(219)220)149(238)188-107(61-90-43-35-42-89-41-29-30-44-93(89)90)144(233)184-102(56-77(5)6)141(230)176-83(14)133(222)175-84(15)134(223)180-99(49-36-55-170-160(167)168)138(227)191-113(68-125(217)218)148(237)186-106(60-88-39-27-24-28-40-88)151(240)198-128(81(12)20-3)156(245)195-109(64-118(164)207)146(235)189-108(62-91-70-171-96-47-32-31-45-94(91)96)145(234)185-104(58-79(9)10)150(239)197-127(80(11)19-2)155(244)183-100(50-52-117(163)206)140(229)200-130(85(16)204)158(247)179-97(132(166)221)48-33-34-54-161/h23-32,35,37-45,47,70-71,76-86,95,97-116,127-131,171,202-205H,18-22,33-34,36,46,48-69,72-75,161-162H2,1-17H3,(H2,163,206)(H2,164,207)(H2,165,208)(H2,166,221)(H,169,174)(H,172,224)(H,173,225)(H,175,222)(H,176,230)(H,177,209)(H,178,210)(H,179,247)(H,180,223)(H,181,228)(H,182,236)(H,183,244)(H,184,233)(H,185,234)(H,186,237)(H,187,242)(H,188,238)(H,189,235)(H,190,226)(H,191,227)(H,192,231)(H,193,243)(H,194,246)(H,195,245)(H,196,232)(H,197,239)(H,198,240)(H,199,248)(H,200,229)(H,201,241)(H,211,212)(H,213,214)(H,215,216)(H,217,218)(H,219,220)(H4,167,168,170)/t80-,81+,82-,83-,84-,85-,86-,95-,97-,98?,99-,100+,101+,102-,103+,104+,105+,106-,107?,108+,109-,110+,111+,112+,113-,114+,115+,116+,127+,128-,129+,130+,131+/m0/s1
Standard InChI Key: LDCVSMFHMFSLDH-ZMHCSVTMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3486.90 | Molecular Weight (Monoisotopic): 3484.7416 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wiśniewski K, Sueiras-Diaz J, Jiang G, Galyean R, Lu M, Thompson D, Wang YC, Croston G, Posch A, Hargrove DM, Wiśniewska H, Laporte R, Dwyer JJ, Qi S, Srinivasan K, Hartwig J, Ferdyan N, Mares M, Kraus J, Alagarsamy S, Rivière PJ, Schteingart CD.. (2016) Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance., 59 (7): [PMID:26986178] [10.1021/acs.jmedchem.5b01909] |
Source(1):